Product Description
CBP-201 blocks inflammatory signaling by both IL-4 and IL-13. CBP-201 binds to a region of IL-4Ralpha that is distinct from that bound by dupilumab (an antibody that targets IL-4Ralpha and is marketed as Dupixent). (Sourced from: https://www.connectbiopharm.com/pipeline/cbp-201/)
Mechanisms of Action: IL4 Antagonist, IL13 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Connect Biopharma
Company Location: Western America
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, China, Georgia, Serbia, United Kingdom, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Connect Biopharma announced they will present P2 Chronic Obstructive Pulmonary Disease results in 3Q26 for Rademikibart
- Clinical Outcomes Reported - Connect Biopharma presented P2 Asthma results on 2026-09-15 for Rademikibart
- Clinical Outcomes Reported - Connect Biopharma announced they will present P2 Asthma|Chronic Obstructive Pulmonary Disease results in 3Q26 for Rademikibart
Highest Development Phases
Phase 3: Dermatitis, Atopic
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07705737 |
CBP-201-209 | P2 |
Recruiting |
Chronic Obstructive Pulmonary Disease|Asthma |
2026-12-01 |
63% |
2026-08-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20242160 |
CTR20242160 | P3 |
Completed |
Dermatitis, Atopic |
2026-02-13 |
2026-04-14 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244210 |
CTR20244210 | P1 |
Completed |
Dermatitis, Atopic |
2025-05-22 |
2025-06-12 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06940141 |
Seabreeze STAT Asthma | P2 |
Completed |
Asthma |
2026-07-17 |
67% |
2026-09-17 |
|
CTR20231224 |
CTR20231224 | P2 |
Completed |
Dermatitis, Atopic |
2024-04-08 |
2026-04-28 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06940154 |
Seabreeze STAT COPD | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2026-07-30 |
67% |
2026-09-17 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
ACTRN12618000756224 |
ACTRN12618000756224 | P1 |
Active, not recruiting |
Dermatitis, Atopic |
2018-11-15 |
2026-02-15 |
Treatments |